Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 401,700 shares, a growth of 6.7% from the October 31st total of 376,600 shares. Based on an average daily volume of 57,800 shares, the short-interest ratio is presently 6.9 days. Approximately 1.7% of the company’s shares are sold short.

Gyre Therapeutics Stock Down 6.9 %

Shares of NASDAQ GYRE opened at $11.01 on Wednesday. The stock has a fifty day simple moving average of $13.47 and a 200-day simple moving average of $12.74. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $30.40.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the period. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP acquired a new stake in shares of Gyre Therapeutics in the third quarter valued at $334,000. WINTON GROUP Ltd purchased a new position in Gyre Therapeutics in the second quarter valued at $220,000. Finally, Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics during the 2nd quarter worth $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.